retatrutide triple hormone receptor agonist benefits Diagram showing the mechanism of action of Lilly's triple agonist achieves 16.8%

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists form classes of medicines that can help treat conditions such as type 2 diabetes and obesity

In January 2025, the firm published results of a Phase 2 trial for VK2735 with strong potential, including up to nearly 15% of baseline body weight lost in trial participants without a clear plateau

Managing side effects after retatrutide injections Side effects are part of the retatrutide experience, especially during titration

Its mechanism is broader, its attention curve is steeper, and its data has made a much louder impact

No serious cardiac events were reported at elevated rates